Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484275 · ClinicalTrials.gov registry record · Phase 2
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT01484275 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 85 participants.
The verdict
NCT01484275, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of siltuximab compared with placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) in patients with high-risk smoldering multiple myeloma (SMM).
Interventions
- DRUG Placebo
- DRUG Siltuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2012-03-01 |
| Est. Completion | 2019-08-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01484275
The ClinicalTrials.gov registry entry for NCT01484275 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01484275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01484275 about?
NCT01484275 is a clinical study titled "A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma". The purpose of this study is to evaluate the safety and efficacy of siltuximab compared with placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) in patients with high-risk smoldering multiple myeloma (SMM).
What is the current status of trial NCT01484275?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2012-03-01. Estimated completion is 2019-08-21.
What interventions are being tested in trial NCT01484275?
The interventions under investigation include: Placebo (DRUG), Siltuximab (DRUG).
Who is sponsoring clinical trial NCT01484275?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.